{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-348.5","upperLimit":"356.5","value":"35.5"},{"groupId":"OG001","lowerLimit":"-162","upperLimit":"75","value":"-115"},{"groupId":"OG002","lowerLimit":"-172","upperLimit":"-172","value":"-172"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"End of cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-962.5","upperLimit":"198.5","value":"-164.5"},{"groupId":"OG001","lowerLimit":"18","upperLimit":"359","value":"211"},{"groupId":"OG002","lowerLimit":"-81","upperLimit":"-81","value":"-81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Treatment discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-177","upperLimit":"443","value":"-56"},{"groupId":"OG001","lowerLimit":"-152","upperLimit":"728","value":"275"},{"groupId":"OG002","lowerLimit":"-16","upperLimit":"-16","value":"-16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"6-month follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"604","upperLimit":"604","value":"604"},{"groupId":"OG001","lowerLimit":"-97","upperLimit":"692","value":"154"},{"groupId":"OG002","lowerLimit":"128","upperLimit":"128","value":"128"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"12-month follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Differences from baseline (specified follow-up assessment minus baseline) in absolute CD8 counts.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Phase I, Arm A (VR-DA-EPOCH) with Vorinostat at 300 mg once a day on days 1-5 of a cycle (Phase I Dose Level 1)","id":"OG000","title":"Phase I: VR-DA-EPOCH, Dose Level 1"},{"description":"Phase I, Arm A (VR-DA-EPOCH) with Vorinostat at 400 mg once a day on days 1-5 of a cycle (Phase I Dose Level 2)","id":"OG001","title":"Phase I: VR-DA-EPOCH, Dose Level 2"},{"description":"Arm C (VR-CHOP) with Vorinostat at 300 mg once a day on days 1-5 of a cycle (Phase I Dose Level 1 for low risk participants). This arm was discontinued due to low accrual.","id":"OG002","title":"Phase I: VR-CHOP, Dose Level 1"}],"paramType":"MEDIAN","populationDescription":"Eligible participants who returned for follow-up with evaluable data.","reportingStatus":"POSTED","timeFrame":"Baseline up to 12 months","title":"Change in CD8 Cell Counts (Phase I)","type":"SECONDARY","unitOfMeasure":"cells/mm^3"}